Reply to G. Sauter et al

Journal of Clinical Oncology

Volumn 27, Issue 30, 2009, Pages

  Hammond, Elizabeth H ^a   Wolff, Antonio C ^b   Hayes, Daniel F ^c   Schwartz, Jared N ^d  

^a INTERMOUNTAIN HEALTHCARE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d PRESBYTERIAN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; K RAS PROTEIN; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

ALGORITHM; ANEUPLOIDY; BREAST CANCER; CANCER GENETICS; CLINICAL TRIAL; COLON CANCER; CONSENSUS; DIAGNOSTIC ACCURACY; EVIDENCE BASED PRACTICE; FALSE NEGATIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; GENOMICS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LABORATORY; LETTER; MEDICAL SOCIETY; METASTASIS; PATHOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REPRODUCIBILITY; STANDARDIZATION; TOTAL QUALITY MANAGEMENT;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; LYMPH NODES; LYMPHATIC METASTASIS;

EID: 77649101487     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.0366     Document Type: Letter

References (19)

1. Sauter G, Lee J, Bartlett JM, et al: Guidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerations. J Clin Oncol 27:1323-1333, 2009
2. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
3. Wolff AC, Hammond EH, Schwartz JN, et al: In Reply. J Clin Oncol 25:4021-4023, 2007
4. Perez EA, Suman VJ, Davidson NE, et al: HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032-3038, 2006
5. Paik S, Bryant J, Tan-Chiu E, et al: Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854, 2002
6. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
8. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
9. Lohr KN, Eleazer K, Mauskopf J: Health policy issues and applications for evidence-based medicine and clinical practice guidelines. Health Policy 46:1-19, 1998
10. O'Malley FP, Thomson T, Julian J, et al: HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Arch Pathol Lab Med 132:61-65, 2008
11. Umemura S, Osamura RY, Akiyama F, et al: What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard. Am J Clin Pathol 130:883-891, 2008
12. Yaziji H, Taylor CR: Begin at the beginning, with the tissue! The key message underlying the ASCO/CAP task force guideline recommendations for HER2 testing. Appl Immunohistochem Mol Morphol 15:239-241, 2007
13. Dowsett M, Hanby AM, Laing R, et al: HER2 testing in the UK: Consensus from a national consultation. J Clin Pathol 60:685-689, 2007
14. Carlson RW, Moench SJ, Hammond ME, et al: HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 4:S1-S22; quiz S23-S24, 2006 (suppl 3)
15. Press MF, Finn RS, Cameron D, et al: HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861-7870, 2008
16. Di Leo A, Gomez HL, Aziz Z, et al: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544-5552, 2008
17. Vance GH, Barry TS, Bloom KJ, et al: Genetic heterogeneity in HER2 testing in breast cancer: Panel summary and guidelines. Arch Pathol Lab Med 133:611-612, 2009
18. Wasielewski R, Hasselmann S, Ruschoff J, et al: Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch 453: 537-543, 2008
19. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009